Back
Junctional adhesion molecule B interferes with angiogenic VEGF/VEGFR2 signaling.
Journal article

Junctional adhesion molecule B interferes with angiogenic VEGF/VEGFR2 signaling.

  • Meguenani M *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Miljkovic-Licina M *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Fagiani E *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Ropraz P *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Hammel P *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Aurrand-Lions M *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Adams RH *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Christofori G *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany.
  • Imhof BA *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany sarah.garrido-urbani@unige.ch beat.imhof@unige.ch.
  • Garrido-Urbani S *Department of Pathology and Immunology, Medical Faculty, University Medical Center, University of Geneva, Geneva, Switzerland; Department of Biomedicine, Institute of Biochemistry and Genetics, University of Basel, Basel, Switzerland; Unité Mixte de Recherche 1068, Centre de Recherche en Cancérologie de Marseille, Institut National de la Santé et de la Recherche Médicale, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Marseille Université, Marseille, France; Unité Mixte de Recherche 7258, Centre National de la Recherche Scientifique, Marseille, France; Department of Tissue Morphogenesis, Max-Planck-Institute for Molecular Biomedicine, Münster, Münster, Germany; and Faculty of Medicine, University of Münster, Münster, Germany sarah.garrido-urbani@unige.ch beat.imhof@unige.ch.
Show more…
  • 2015-04-26
Published in:
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology. - 2015
aortic ring
endothelial cells
tumor angiogenesis
Animals
Cell Adhesion Molecules
Cell Line, Tumor
Female
Mice
Mice, Inbred C57BL
Neovascularization, Pathologic
Signal Transduction
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
English De novo formation of blood vessels is a pivotal mechanism during cancer development. During the past few years, antiangiogenic drugs have been developed to target tumor vasculature. However, because of limitations and adverse effects observed with current therapies, there is a strong need for alternative antiangiogenic strategies. Using specific anti-junctional adhesion molecule (JAM)-B antibodies and Jam-b-deficient mice, we studied the role in antiangiogenesis of JAM-B. We found that antibodies against murine JAM-B, an endothelium-specific adhesion molecule, inhibited microvessel outgrowth from ex vivo aortic rings and in vitro endothelial network formation. In addition, anti-JAM-B antibodies blocked VEGF signaling, an essential pathway for angiogenesis. Moreover, increased aortic ring branching was observed in aortas isolated from Jam-b-deficient animals, suggesting that JAM-B negatively regulates proangiogenic pathways. In mice, JAM-B expression was detected in de novo-formed blood vessels of tumors, but anti-JAM-B antibodies unexpectedly did not reduce tumor growth. Accordingly, JAM-B deficiency in vivo had no impact on blood vessel formation, suggesting that targeting JAM-B in vivo may be offset by other proangiogenic mechanisms. In conclusion, despite the promising effects observed in vitro, targeting JAM-B during tumor progression seems to be inefficient as a stand-alone antiangiogenesis therapy.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/109187
Statistics
Document views: 35 File downloads: